Infographic | July 16, 2019

How Do Experience And Capacity Impact Small Molecule API Outsourcing?

Source: ISR Reports

In Q2 2018, ISR asked 60 outsourcers of small molecule drug substance manufacturing to select from four different reasons that manufacturing may be split between in-house and external resources. The data below show how respondents rated their organization’s experience and capacity with respect to outsourcing manufacturing of the active pharmaceutical ingredients. Interestingly, one-quarter of respondents (24%) stated their company lacks both capacity and experience to manufacture drug substance. To learn more, follow the link to the Development and Commercial Manufacturing Outsourcing Models report preview. 


Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Pharmaceutical Online? Subscribe today.

Subscribe to Pharmaceutical Online X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Pharmaceutical Online